- SEK27.86bn
- SEK25.86bn
- SEK2.00bn
Brief: BioArctic Partner Submits Leqembi sBLA To FDA
Brief: Bioarctic's Says As Per Eisai's Simulation Leqembi Sales Will Reach JPY 290 Bln For Financial Year 2026
Europe Research Roundup: Heineken NV, Integrafin Holdings Plc, Kingfisher
Brief: Bioarctic Proposes That No Dividend Is To Be Paid For 2023
Brief: BioArctic Says Sales Of Leqembi Totaled 1.1 Billion Yen In Q4 2023
Eisai expects 1,500 Alzheimer's patients in China launch, sees ‘huge’ growth
Eisai expects 1,500 Alzheimer's patients in China launch, sees ‘huge’ growth
Brief: BioArctic's Leqembi Approved For Treatment Of Alzheimer's Disease In China
Brief: BioArctic Says Leqembi To Be Launched In Japan For Alzheimer's Disease On December 20
GS starts BioArctic at 'buy' on strong Alzheimer's opportunity
Brief: BioArctic Q3 Operating Profit SEK 131 Million
Brief: Bioarctic AB Says Leqembi® Q3 2023 Sales 0.4 Billion Yen
Injected version of Eisai/Biogen Alzheimer's drug works as well as IV Leqembi (updated)
Injected version of Eisai/Biogen Alzheimer's drug effective, side effects higher
Brief: Bioarctic Leqembi Intravenous Infusion Approved In Japan
Brief: Bioarctic Receives Patent In Japan
Brief: BioArctic Q2 Net Revenues Down At SEK 2.7 Mln
Corrected: BRIEF-BioArctic Q2 Operating Profit SEK -100.9 Million
Brief: FDA Grants Traditional Approval For Leqembi® (Lecanemab-Irmb) For The Treatment Of Alzheimer's Disease